Abdul-Karim Raghad M, Cowey C Lance
Baylor Sammons Cancer Center.
Melanoma and Genitourinary Oncology Program, Baylor University Medical Center, Sammons Cancer Center Texas Oncology.
Cancer Manag Res. 2017 Sep 25;9:433-442. doi: 10.2147/CMAR.S92546. eCollection 2017.
The last several years have seen a dramatic rise in the number of effective therapies that have been shown to improve survival outcomes for patients with advanced melanoma. Among these treatments are the immune checkpoint inhibitors, a new class of immunotherapy, that have demonstrated the ability to improve both response rates and survival outcomes. Pembrolizumab, an immune checkpoint inhibitor that blocks the negative regulatory PD-1 receptor on T-cell lymphocytes, has shown improved efficacy compared to standard therapies with an acceptable tolerability profile. Additionally, this agent is being evaluated in adjuvant and combination trial strategies that have great potential to further advance outcomes. This review focuses on the advances that pembrolizumab has made in melanoma and what studies are upcoming that could change the future of melanoma treatment yet again.
在过去几年中，已证实能改善晚期黑色素瘤患者生存结局的有效疗法数量急剧增加。这些治疗方法包括免疫检查点抑制剂，这是一类新型免疫疗法，已证明其有能力提高缓解率和生存结局。派姆单抗是一种免疫检查点抑制剂，可阻断T淋巴细胞上的负调节性PD-1受体，与标准疗法相比，其疗效有所提高，且耐受性良好。此外，该药物正在辅助治疗和联合试验策略中进行评估，这些策略极有可能进一步改善治疗效果。本综述重点关注派姆单抗在黑色素瘤治疗方面取得的进展，以及即将开展的哪些研究可能再次改变黑色素瘤治疗的未来。
